The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer—The IKF/AIO-ADJUBIL trial.
 
Thorsten Goetze
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Foundation Medicine; Incyte; Lilly; MSD Oncology; Novartis; Roche; SERVIER
Speakers' Bureau - Lilly; MSD Oncology
Research Funding - AstraZeneca (Inst); Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss; Incyte (Inst); Lilly (Inst)
 
Arndt Vogel
Honoraria - Amgen; AstraZeneca/MedImmune; BeiGene; Boehringer Pharma GmbH; Boston Scientific; Bristol-Myers Squibb; Daichi-Sankyo; Eisai; GlaxoSmithKline; Incyte; Ipsen; Janssen; Lilly; MSD; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Sirtex Medical; Taiho Oncology; TERUMO
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Boehringer Pharma GmbH; BTG; Daichi-Sankyo; EISAI; Incyte; IPSEN; Lilly; Novartis; Pierre Fabre; Roche; Sirtex Medical; Taiho Oncology; Taiho Oncology; Terumo
Research Funding - Novartis
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Lilly; MSD; Roche
 
Maria Gonzalez-Carmona
No Relationships to Disclose
 
Timorshah Habibzada
No Relationships to Disclose
 
Johanna Reinecke
No Relationships to Disclose
 
Marius Adler
No Relationships to Disclose
 
Daniel Pink
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Deciphera (Inst); PharmaMar (Inst); SpringWorks Therapeutics (Inst)
Speakers' Bureau - Boehringer Ingelheim (Inst); Deciphera (Inst); PharmaMar (Inst)
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); PharmaMar (Inst); Recordati (Inst); Roche (Inst)
 
Thomas Ettrich
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Ipsen; Lilly; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER; Takeda
Research Funding - Baxalta/Shire; Lilly (Inst)
Travel, Accommodations, Expenses - Ipsen; Lilly
 
Christoph Roderburg
Research Funding - SERVIER (Inst)
 
Ursula Pession
No Relationships to Disclose
 
Anna Saborowski
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; MSD; Roche; Servier
Consulting or Advisory Role - BMS; Eisai; Incyte; MSD; Roche/Genentech
Travel, Accommodations, Expenses - Eisai; MSD; Pierre Fabre; SERVIER
 
Florian van Boemmel
No Relationships to Disclose
 
Thomas Wehler
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Novocure; Pfizer; Roche/Genentech
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Research Funding - AstraZeneca; Boehringer Ingelheim; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Celgene; Janssen; Pfizer; Roche/Genentech
 
Claus-Henning Koehne
No Relationships to Disclose
 
Marina Schaaf
No Relationships to Disclose
 
Disorn Sookthai
Stock and Other Ownership Interests - Bayer
 
Regina Eickhoff
No Relationships to Disclose
 
Miriam Pons
No Relationships to Disclose
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Frankfurter Institut für Klinische Krebsforschung IKF GmbH
Consulting or Advisory Role - Bristol-Myers Squibb; Eli Lilly Germany; Merck Sharp & Dohme
Speakers' Bureau - MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Immutep; Ipsen; Lilly; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma
 
Dominik Modest
Honoraria - 21up; Amgen; AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Cor2Ed; GlaxoSmithKline; IKF Klinische Krebsforschung; Lilly; Merck; Merck Serono; Onkowissen; Pierre Fabre; Regeneron; Rottapharm Biotech; Seagen; SERVIER; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Cor2Ed; GlaxoSmithKline; Incyte; Lilly; Merck Serono; Onkowissen; Pierre Fabre; Regeneron; SERVIER; Takeda
Research Funding - Amgen (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Serono; SERVIER